Pyrenebutyrate Pt(IV) Complexes with Nanomolar Anticancer Activity.
activation by reduction
anticancer agents
cellular uptake
cytotoxicity
platinum(IV) prodrugs
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
13 Sep 2023
13 Sep 2023
Historique:
received:
22
08
2023
revised:
06
09
2023
accepted:
10
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Research on platinum-based anticancer drugs continuously strives to develop new non-classical platinum complexes. Pt(IV) prodrugs are the most promising, and their activation-by-reduction mechanism of action is being explored as a prospect for higher selectivity and efficiency. Herein, we present the anticancer potency and chemical reactivity of Pt(IV) complexes formed by linking pyrene butyric acid with cisplatin. The results from cytotoxicity screening on 10 types of cancer cell lines and non-malignant cells (HEK-293) indicated IC
Identifiants
pubmed: 37765279
pii: pharmaceutics15092310
doi: 10.3390/pharmaceutics15092310
pmc: PMC10537052
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bulgarian Science Fund
ID : КП-06-Н59/9
Références
J Inorg Biochem. 2017 Dec;177:1-7
pubmed: 28918353
Mol Cancer. 2009 Jun 23;8:39
pubmed: 19549337
Dalton Trans. 2021 Apr 7;50(13):4663-4672
pubmed: 33725031
J Inorg Biochem. 2020 Sep;210:111125
pubmed: 32521289
Methods Mol Biol. 2011;787:137-43
pubmed: 21898233
J Phys Chem Lett. 2010;1:1312-1315
pubmed: 20436938
Anticancer Res. 2003 May-Jun;23(3C):2757-65
pubmed: 12926110
Eur J Med Chem. 2011 Nov;46(11):5456-64
pubmed: 21940073
Methods Enzymol. 1990;182:50-68
pubmed: 2314256
J Inorg Biochem. 2016 Jul;160:85-93
pubmed: 26775068
Int J Mol Sci. 2022 Jun 25;23(13):
pubmed: 35806087
J Med Chem. 2020 Jun 11;63(11):6096-6106
pubmed: 32401032
Dalton Trans. 2016 Aug 16;45(33):13214-21
pubmed: 27488015
Inorg Chem. 2012 Jul 2;51(13):7119-24
pubmed: 22716166
Chem Sci. 2016 Mar 1;7(3):2381-2391
pubmed: 29997781
Chemistry. 2011 Feb 7;17(6):1966-71
pubmed: 21274948
Eur J Pharm Sci. 2020 Dec 1;155:105545
pubmed: 32927069
Oncology. 2005;68(1):2-9
pubmed: 15741753
Met Based Drugs. 2009;2009:348916
pubmed: 19587824
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Int J Mol Sci. 2021 Apr 07;22(8):
pubmed: 33917027
ACS Chem Biol. 2006 Jun 20;1(5):299-303
pubmed: 17163758
FEBS J. 2019 Feb;286(3):441-455
pubmed: 29931808
Angew Chem Int Ed Engl. 2018 Jul 16;57(29):9098-9102
pubmed: 29806087
J Med Chem. 2007 Jul 26;50(15):3403-11
pubmed: 17602547
J Med Chem. 2005 Dec 15;48(25):8060-9
pubmed: 16335930
Chemistry. 2013 Jan 28;19(5):1672-6
pubmed: 23255183
J Inorg Biochem. 2014 Nov;140:72-9
pubmed: 25063910
J Inorg Biochem. 2015 Dec;153:259-271
pubmed: 26365319
Dalton Trans. 2019 Nov 26;48(46):17228-17240
pubmed: 31728483
Pharmaceutics. 2022 Sep 27;14(10):
pubmed: 36297500
Sci Rep. 2016 Jul 11;6:29367
pubmed: 27404565
ChemMedChem. 2018 Jun 20;13(12):1210-1217
pubmed: 29637702
J Med Chem. 2022 Jun 23;65(12):8227-8244
pubmed: 35675651
Pharmaceutics. 2022 Apr 03;14(4):
pubmed: 35456621
Dalton Trans. 2021 Jun 21;50(23):8167-8178
pubmed: 34031671
Chem Asian J. 2016 Feb 18;11(4):474-7
pubmed: 26629785
Chem Sci. 2018 Apr 24;9(18):4299-4307
pubmed: 29780561
Recent Pat Anticancer Drug Discov. 2006 Jun;1(2):285-95
pubmed: 18221042
Chem Biodivers. 2015 Apr;12(4):559-74
pubmed: 25879501
J Inorg Biochem. 2019 Feb;191:77-84
pubmed: 30471522